Austrália - inglês - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate; macrogol 6000; propylene glycol; colloidal anhydrous silica; magnesium stearate; povidone; purified talc; titanium dioxide; hypromellose - treatment of type 2 diabetes mellitus in adults, particularly in over weight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. metformin may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; macrogol 6000; titanium dioxide; propylene glycol; maize starch; colloidal anhydrous silica; sodium starch glycollate; magnesium stearate; hypromellose; purified talc - treatment of type 2 diabetes mellitus in adults, particularly in over weight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. metformin may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; macrogol 6000; titanium dioxide; povidone; magnesium stearate; maize starch; propylene glycol; sodium starch glycollate; hypromellose - treatment of type 2 diabetes mellitus in adults, particularly in over weight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. metformin may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - clindamycin hydrochloride, quantity: 162.868 mg - capsule, hard - excipient ingredients: lactose; purified talc; microcrystalline cellulose; povidone; magnesium stearate; sodium starch glycollate; titanium dioxide; brilliant blue fcf; purified water; gelatin; sodium lauryl sulfate; tartrazine; propylene glycol; ethanol; isopropyl alcohol; shellac; tert-butyl alcohol; sodium hydroxide - clindamycin lu (clindamycin hydrochloride) capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin lu capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate.,anaerobes:,serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci: serious respiratory tract infections; serious skin and skin structure infections, septicaemia,staphylococci: serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis,pneumococci: serious respiratory tract infections,adjunctive therapy: in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy.,bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clindamycin hydrochloride, quantity: 162.87 mg - capsule, hard - excipient ingredients: shellac; magnesium stearate; titanium dioxide; iron oxide black; purified talc; maize starch; lactose monohydrate; gelatin; propylene glycol; strong ammonia solution - clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. pneumococci serious respiratory tract infections. adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 87.2 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; sucrose; titanium dioxide; indigo carmine; ammonium chloride; sodium starch glycollate type b; lactose monohydrate; gelatin; macrogol 6000; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 65.4 mg - capsule, hard - excipient ingredients: sodium starch glycollate type b; titanium dioxide; sucrose; macrogol 6000; indigo carmine; gelatin; sodium lauryl sulfate; ammonium chloride; purified water; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 43.6 mg - capsule, hard - excipient ingredients: macrogol 6000; ammonium chloride; lactose monohydrate; purified water; titanium dioxide; sucrose; gelatin; sodium starch glycollate type b; sodium lauryl sulfate; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 21.8 mg - capsule, hard - excipient ingredients: gelatin; lactose monohydrate; sodium starch glycollate type b; purified water; sucrose; titanium dioxide; ammonium chloride; sodium lauryl sulfate; indigo carmine; macrogol 6000; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 87.2 mg - capsule, hard - excipient ingredients: macrogol 6000; titanium dioxide; lactose monohydrate; sodium starch glycollate type b; gelatin; ammonium chloride; indigo carmine; sodium lauryl sulfate; purified water; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.